Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Hyperuricemia, Gout
Interventions: ALLN-346, Placebo; Drug
Lead sponsor: Allena Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin, Placebo, Sitagliptin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 678 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Concord, California • Greenbrae, California + 21 more

Conditions: Alzheimer's Disease
Interventions: Placebo Capsule(s) Once a Day by Mouth, Nilotinib Capsule(s) Once a Day by Mouth; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 50 Years to 85 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Analgesia
Interventions: KP-1199, Placebo oral capsule, Oxycodone oral capsule; Drug
Lead sponsor: Kalyra Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: HIV
Interventions: Atazanavir, Raltegravir, Ritonavir, Tenofovir/Emtricitabine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 9
States / cities: Phoenix, Arizona • New Haven, Connecticut • Washington D.C., District of Columbia + 5 more

Conditions: Covid19, Sequelae of; Infection, Cognitive Symptom
Interventions: Niagen; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Probiotic- Bifidobacterium Bifidum, Sugar Pill, Probiotic- Lactobacillus helveticus, Probiotic- Bifidobacterium longum ss. Infantis R0033; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 583 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy
Interventions: EDP-788, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Early-stage Parkinson's Disease
Interventions: UCB0599, Placebo; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 57
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more

Conditions: Pmm2-CDG, Phosphomannomutase 2 Deficiency, Phosphomannomutase 2 Congenital Disorder of Glycosylation, Phosphomannomutase II Congenital Disorder of Glycosylation, Phosphomannomutase II Deficiency
Interventions: Epalrestat, Placebo; Drug
Lead sponsor: Maggie's Pearl, LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions: Placebo, Linaclotide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,722 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 52
States / cities: Huntsville, Alabama • North Little Rock, Arkansas • Phoenix, Arkansas + 49 more

Conditions: Gout
Interventions: High Dose Colchicine (4.8 mg total dose), Low Dose Colchicine (1.8mg total dose), Placebo Control; Drug · Other
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 83
States / cities: Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 78 more

Conditions: Marijuana Abuse
Interventions: AEF0117, Placebo oral capsule; Drug
Lead sponsor: Aelis Farma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 11
States / cities: Phoenix, Arizona • Garden Grove, California • Los Angeles, California + 8 more

Conditions: Obesity
Interventions: NT-0796, Placebo; Drug
Lead sponsor: Rezera (formerly NodThera Limited); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Mesa, Arizona • Hialeah, Florida • Jacksonville, Florida + 6 more

Conditions: Posttraumatic Stress Disorder
Interventions: Modafinil; Drug
Lead sponsor: Biomedical Research Foundation; Other
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: North Little Rock, Arkansas

Conditions: Pain, Neuropathic, Pain, Inflammatory
Interventions: AFA-281; Drug
Lead sponsor: Afasci Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Alamitos, California

Conditions: Energy, Focus, Caffeine Withdrawal
Interventions: Paraxanthine 200 mg, Paraxanthine 300 mg, Placebo; Other
Lead sponsor: Iovate Health Sciences International Inc; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Severe Asthma
Interventions: Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more

Conditions: Huntington Disease
Interventions: Pridopidine, Placebo; Drug
Lead sponsor: Prilenia; Industry
Eligibility: 25 Years and older
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 26
States / cities: Davis, California • San Diego, California • Englewood, Colorado + 22 more

Conditions: Healthy Participants, Upper Gastrointestinal Discomfort
Interventions: Limosilactobacillus reuteri DSM 17648, Placebo; Dietary Supplement
Lead sponsor: Novozymes A/S; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 324 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Lung Transplant
Interventions: Extended-Release Tacrolimus, Immediate-Release Tacrolimus; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C
Interventions: TMC435, Placebo, Peginterferon alpha-2a (PegIFN alpha-2a), Ribavirin (RBV); Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 11
States / cities: Bakersfield, California • Aurora, Colorado • Jacksonville, Florida + 8 more

Conditions: Parkinson's Disease
Interventions: Pioglitazone, placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 30 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 32 more

Conditions: Alzheimer's Disease
Interventions: NGP 555; Drug
Lead sponsor: NeuroGenetic Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Cypress, California

Search by objective public record fields.

Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease

A Single and Multiple Ascending Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of KP-1199

Phase IIB Pilot of Atazanavir + Raltegravir

Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19

The Effect of Probiotics (L. Helveticus, B. Longum, and B. Bifidum) on Immune Function and Digestive Health

Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

MPC-004 for the Treatment of an Acute Gout Flare

Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)

Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)

Modafinil in the Treatment of PTSD (Posttraumatic Stress Disorder)

Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers

Effect of Different Dosages of Paraxanthine, the Major Caffeine Metabolite, on Energy and Focus

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD

Effect of Limosilactobacillus Reuteri DSM 17648 in Healthy Adults Reporting Upper Gastrointestinal Discomfort

Envarsus XR in Lung Transplant

An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

Pioglitazone in Early Parkinson's Disease

Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)